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Hematopoietic stem cell transplants (HCT) for older
patients with AML have increased signiﬁcantly over the past
decade, associated with the use of reduced intensity condi-
tioning (RIC) regimen. Transplant outcome based upon
disease status (high vs intermediate risk) and donor source
(related vs unrelated) is now examined.
Methods: Between 2007-2012, 50 patients (55-70 years,
median 61) with AML in CR1 (n¼41) or >CR1 (n¼9) were
prospectively enrolled on an IRB-approved clinical trial using
a RIC regimen. Donor sources included either a related (RD)
(n¼23) or unrelated donor (UD)(n¼27), if a suitable RD was
not available. All patients were conditioned with ﬂudarabine
(160 mg/m2) + busulfan (6.4 mg/m2) [FluBu2]; UD recipients
additionally received 200cGy TBI on day -1 pre-transplant.
GVHD prophylaxis was tacrolimus and mycophenolate. No
anti-thymocyte globulin (ATG) was administered pre-HCT.
Patients exhibited high risk (n¼21) or intermediate risk
(n¼29) disease at initial diagnosis, as deﬁned by cytogenetic
and molecular criteria. Patients with good risk disease were
excluded from analysis.
Results: For the entire cohort, the 1y and 3y relapse free
survival (RFS) was 56% (95% CI: 43-69) and 43% (95% CI: 28-
58) respectively, with 1y and 3y overall survival (OS) rates
58% (95% CI:46-74) and 44% (95% CI: 27-62%). Patients with
intermediate risk disease experienced 1y and 3y RFS of
748.5% and 3y RFS 6210.5%. By comparison, transplant
outcomes were poor for patients with high risk disease, with
1y and 3y RFS only 3110% and 1310% (Figure 1). There was
no signiﬁcant difference in 1y RFS between UD and RD
recipients [629.5% vs 4811%] or 3y RFS [4411% vs
4012%], P ¼ .42 (Figure 1). There was no difference in
outcome by age, with 3y RFS 42.511% for patients 55-59 yrs
(n¼20) and 4012% for patients 60-70 yrs (n¼30), P ¼ .54.
The median donor age was 37 yrs (range 19-50) for UD and
58 yrs (range 42-70) for RD recipients. The median CD34 cell
dose infused was 5.0 x 10(6)/kg in both cohorts [range UD:
1.2 -8.3 x 10(6), RD: 1.9 -9.8 x 10(6)]. There was no difference
in time to neutrophil engraftment, with both cohorts
engrafting a median 12 days post-transplant. Primary graft
failure occurred in 1 (3.4%) UD recipient, who received an
HLAmismatched graft. No secondary graft failure occurred in
either cohort. Day 100 CD33 chimerism was all donor in all
UD cases, and in 75% of RD recipients. Grade 2-4 acute GVHD
developed in 44% URD and 30% RD respectively, with grade
3-4 acute GVHD in 7% UD and 10% RD.
Conclusion: Reduced intensity transplants for older patients
with intermediate risk AML are associatedwith high RFS rates.
In contrast, transplant outcomes for older patients presenting
with high risk disease are poor using a reduced intensity
regimen.No survival advantage isnotedbydonor source (RDorUD). Donor stem cell yield and hematologic recovery were
equivalent in RD and UD transplants for older AML patients.
Figure 1.
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Background: Historically, inpatient academic medical center
(AMC) patient care has been delivered by faculty physicians
in conjunctionwith physicians-in-training (house-ofﬁcers or
HO). Alternative stafﬁng models have emerged secondary to
Accreditation Council for Graduate Medical Education work-
hour restrictions. Our institution expanded the Physician
Assistant (PA) inpatient oncology services to accommodate
such changes. The purpose of this study was to assess the
quality of subspecialized leukemia care provided by our PA
service compared to traditional HO models.
Methods: Data was retrospectively collected on all patients
admitted to theHOor PAhematologicmalignancy services for
re-induction chemotherapy for acute myelogenous leukemia
from January 2008 through January 2012. The same attending
pool rotatedonboth theHOandPAservices. Primaryoutcome
measures were length of stay and mortality. Secondary
outcomes included readmissions within 14 and 30 days, ICU
transfers, number of consults requested, and total studies
ordered (CXR, CT MRI and Ultrasound).
Results: During the study period, 95 patients were admitted
for re-induction chemotherapy. Forty-seven patients (49.5%)
were admitted to HO and 48 patients (50.5%) admitted to
PAs. Demographic data was similar between the two
services. Length of stay was signiﬁcantly different between
the two services with a mean of 36.8 days on the HO service
compared to 30.9 days on the PA service (P¼ .03). The 14 day
readmission rates also differed signiﬁcantly and were 10.6%
(5/47) for HO services and zero for the PA service (P ¼ .03).
The mean number of consults on the HO was 2.11 (0-5
consults) versus 1.47 (0-4 consults) on the PA service (P ¼
.03). Mortality, ICU transfers, and the numbers of radiologic
studies ordered were not signiﬁcantly different between the
two groups.
Discussion: The data suggests equivalent mortality rates and
ICU transfers in the two models with a decrease in length of
stay and readmission rates for those cared for on the PA
service. In order to verify these results, a prospective
randomized trial comparing the two care models is needed.
